When it comes to the three biotech stocks discussed in today’s article, all of which are down 45% or more from their 52-week highs, should they get swept out with some portfolio spring cleaning – or do they still have a chance to blossom in the future despite taking a beating? For the author’s assessment, CLICK HERE.
Should These 3 Biotech Stocks Be Excised From Your Portfolio?
